Braeburn Pharmaceuticals

General Information

We are a commercial-stage pharmaceutical company focused on the development and commercialization of novel long-acting medications for serious disorders of the central nervous system, or CNS. Our proprietary implantable and injectable delivery mechanisms provide differentiated solutions for chronic diseases with high unmet medical needs. Our specialty CNS focus is on fast-growing therapeutic areas recognized as serious public health crises, where long-acting technologies offer important benefits such as increased medication compliance, improved patient convenience, reduced risk of abuse and relapse and reduced public health and societal costs.


Employees: 97
Founded: 2012
Contact Information
Address 47 Hulfish Street, Suite 44, Princeton, NJ 08542, US
Phone Number (609) 751-5375
Web Address
View Prospectus: Braeburn Pharmaceuticals
Financial Information
Market Cap $575.4mil
Revenues $0.07 mil (last 12 months)
Net Income $-94.3 mil (last 12 months)
IPO Profile
Symbol BBRX
Exchange NASDAQ
Shares (millions): 7.7
Price range $18.00 - $21.00
Est. $ Volume $150.0 mil
Manager / Joint Managers J.P. Morgan/ BofA Merrill Lynch
CO-Managers Deutsche Bank Securities/ Canaccord Genuity
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change